17,261 trials
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547 — NA mg
Chronic Pancreatitis
Primary: VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. — 5.71; 6.04; 4.92; 4.87 units on a scale — p=.25
Asthma
Primary: Rate of Severe Asthma Exacerbations During 6 Months — 0.31; 0.31; 0.26; 0.20 Exacerbations per 6 month — p=0.119
Dyslipidemia
Primary: The Apolipoprotein A-I Fractional Catabolic Rate (FCR) — 0.294; 0.294; 0.295 pools/day — p=>0.5
Adult Primary Hepatocellular Carcinoma · Localized Unresectable Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Progression-free Survival — 65 percentage of participants
Brain and Central Nervous System Tumors
Primary: Progression-free Survival (PFS) Rate at 6 Months — 19 percentage of participants
Bladder Cancer · Urinary Bladder
Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants
Myelodysplastic Syndrome (MDS)
Primary: Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically…
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Incidence of Durable Stable Disease, Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 18 particip[ants
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Grade 3-4 Acute GVHD Rate — 29.4 percentage of participants
Relapsed and/or Refractory Multiple Myeloma
Primary: Percentage of Participants Who Received Treatment Including Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs) — 62.5 Percentage of…
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Disease-free (DFS) or Relapse-free Survival (RFS) Time — 15.9 Months
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants
Graft vs Host Disease
Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants